Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
ImmuneOncia Therapeutics is developing antibodies that target novel immune checkpoints, which could enhance drug efficacy when used in combination with agents that block PD-1 or PD-L1.
A new platform built around recombinant overlapping peptides (ROPs) promises quicker and cheaper production of more effective therapeutic vaccines and diagnostics for cancer and viral infections.
The invention relates to therapeutic compounds and related pharmaceutical compositions that can be used in the prevention and treatment of malaria infection. More specifically, the invention is drawn to compounds that may kill sexual and mosquito stage malaria parasites to block transmission.
Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have new technology based on live attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and multivalent immunogenic compositions comprising Zika vaccines and vaccines for other flaviviruses.
Scientists at the NIAID Vaccine Research Center have developed human monoclonal neutralizing antibodies for treatment and prevention of Ebola Zaire disease.
NIAID researchers have discovered a new critical component of the CD4-binding site in gp120, named CD4-BS2, which is exclusively formed in the trimeric envelope conformation.
NIH researchers have developed a tumor-targeted anthrax based toxin that selectively inactivates the blood vessels within tumors, leading to cancer cell death and tumor necrosis.
BioWin, the health competitiveness cluster of Wallonia, Belgium, is the region’s point of reference across biopharma and medtech. Cancer immunotherapy has rapidly emerged as a focal point of BioWin’s collaborative ecosystem owing to the local high density of cancer and immunology players.
A Dallas-based biotech company is leading a wave of innovation in cancer treatment that is being tailored to the cancer patients who are most likely to respond.
Volition, a life sciences company, has developed an array of simple blood tests to improve the detection of a wide range of cancers at early stages, with the goal of dramatically improving survival rates in patients.